Raymond J. Liu

Hematology | Hematology Oncology

2238 Geary Blvd
8th Floor
Sacramento, CA 94115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancers.

Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancers.

Journal: JCO oncology practice

Published: May 30, 2026

From Silos to Synergy: Building Resilient Multidisciplinary Oncology Teams.

From Silos to Synergy: Building Resilient Multidisciplinary Oncology Teams.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 18, 2026

Response to Yu, Wang, and Ge.

Response to Yu, Wang, and Ge.

Journal: Journal of the National Cancer Institute

Published: April 19, 2026

Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.

Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.

Journal: Advances in therapy

Published: March 17, 2026

Oncologist Perspectives on Timely Hospice Referral: A Qualitative Study.

Oncologist Perspectives on Timely Hospice Referral: A Qualitative Study.

Journal: The American journal of hospice & palliative care

Published: March 07, 2026

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.

Journal: Future oncology (London, England)

Published: December 23, 2025

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer.

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer.

Journal: JCO oncology practice

Published: December 11, 2025

Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort.

Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort.

Journal: ESC heart failure

Published: December 01, 2025

Improving timing and sequencing of postoperative radiation therapy in head and neck cancer.

Improving timing and sequencing of postoperative radiation therapy in head and neck cancer.

Journal: Surgery

Published: October 20, 2025

Publisher Correction: Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence.

Publisher Correction: Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence.

Journal: Oncology and therapy

Published: September 25, 2025

The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.

The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.

Journal: Cancer

Published: September 04, 2025

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.

Journal: Journal of the National Cancer Institute

Published: August 06, 2025

Showing 1-12 of 85

Last Updated: 09/26/2026